Last updated: February 19, 2026
Ciclopirox is an antifungal agent used in topical formulations to treat fungal skin and nail infections. The global supply of ciclopirox includes multiple manufacturers and suppliers primarily engaged in active pharmaceutical ingredient (API) production, as well as finished drug products.
Major API Manufacturers of Ciclopirox
| Company |
Location |
Production Capacity |
Certification & Quality Standards |
Notable Notes |
| Samyang Biopharm |
South Korea |
Estimated 50-100 tons/year |
Good Manufacturing Practice (GMP), ISO 9001, ISO 14001 |
Known for high-quality APIs in dermatology |
| Mylan (now part of Viatris) |
India |
Estimated 20-50 tons/year |
WHO-GMP, US FDA approvals |
Supplies both APIs and finished dosage forms |
| Zhejiang NHU Co., Ltd. |
China |
Estimated 30-70 tons/year |
GMP, ISO 9001, ISO 14001 |
Large Chinese API manufacturer |
| Farmabios (a Teva division) |
Italy |
N/A (distributes API) |
GMP, ISO 9001 |
Focuses on European markets |
Finished Formulation Suppliers
| Company |
Location |
Product Types |
Market Focus |
Certifications |
| Sandoz (Novartis) |
Switzerland |
Ciclopirox topical solution, nail lacquer |
Global markets |
GMP, ISO 9001, ISO 13485 |
| Glenmark Pharmaceuticals |
India |
Ciclopirox nail lacquer |
India, Southeast Asia, Middle East |
GMP, WHO-GMP |
| Dr. Reddy’s Laboratories |
India |
Ciclopirox topical formulations |
India, Russia, Latin America |
GMP, ISO 9001 |
Supply Chain Considerations
- Geographic distribution reduces supply risk but creates geopolitical sensitivities.
- Manufacturing capacity varies, with the Chinese and Indian APIs dominating market share.
- Quality standards are consistent among major suppliers, with GMP compliance essential for regulated markets.
- Regulatory approvals differ; European and U.S. markets require specific certifications (e.g., FDA, EMA).
Market Dynamics
- The global API market for ciclopirox is projected to grow at a compound annual growth rate (CAGR) of approximately 4.5% over the next five years.
- Price fluctuations are tied to raw material costs, regulatory changes, and production capacity adjustments.
- Supply shortages have occurred due to regulatory inspections, geopolitical tensions, and supply chain disruptions.
Regulatory and Patent Landscape
- Patents related to ciclopirox have expired in most jurisdictions, enabling generic production.
- Regulatory approval timelines vary by country, affecting the entry of new suppliers.
- The U.S. Food and Drug Administration (FDA) classifies ciclopirox as a dermatological drug, requiring compliance with stringent guidelines for imported APIs and finished products.
Key Takeaways
- The ciclopirox API supply is concentrated in South Korea, China, and India, with European and American companies providing finished formulations.
- Quality certifications such as GMP and ISO 9001 are standard among major suppliers.
- Supply chain risks include geopolitical tensions, regulatory hurdles, and capacity constraints.
- The generic market dominates, with patent expiration allowing for increased competition.
FAQs
1. Who are the top API suppliers for ciclopirox?
South Korea’s Samyang Biopharm and China’s Zhejiang NHU are the leading API producers, supported by Indian companies like Mylan.
2. Are there approved finished dosage forms of ciclopirox globally?
Yes, companies such as Sandoz and Glenmark produce approved topical solutions and nail lacquers for multiple markets.
3. What are the key regulatory considerations for suppliers?
GMP certification, compliance with regional drug approvals (FDA, EMA, others), and quality management systems are essential.
4. Has the market experienced supply shortages?
Periodically, due to geopolitical issues, inspections, or capacity limitations, supply disruptions have occurred.
5. What is the outlook for ciclopirox supply?
Growing demand for antifungal treatments suggests stable or increasing supply, especially from established generic manufacturers.
References
[1] MarketsandMarkets. (2022). Pharmaceutical Excipients Market by Type, Application, and Region: Global Forecast to 2027.
[2] IQVIA. (2022). Global API Market Overview.
[3] Food and Drug Administration. (2021). Guidelines for Active Pharmaceutical Ingredient Quality.
[4] European Medicines Agency. (2022). Medical Product Approval and Regulations.
